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Liver X receptors (LXRs) are members of the nuclear receptor superfamily of DNA-binding transcription
factors and act as sensors of cholesterol homeostasis. Under normal conditions, when intracellular choles-
terol concentration increases, cells synthesize oxysterols and activate the LXR transcriptional network
to drive cholesterol efflux and reduce cholesterol influx and synthesis. During normal and cancer cell prolif-
eration, there is a net uncoupling between intracellular cholesterol increase and LXR activation resulting from
the reduced intracellular oxysterol concentration. This review dissects the novel mechanisms of a previously
unrecognized metabolic uncoupling, supporting the activation of the LXR axis as a bona fide therapeutic
approach in cancer.Introduction
Cholesterol is an essential component of mammalian cell mem-
branes as well as a precursor of bile acids and steroid hormones
(Simons and Ikonen, 2000). Because of its importance, cells
have evolved complex mechanisms to closely regulate the
abundance and distribution of sterols. The circulating levels of
cholesterol are regulated by a balance among intracellular
synthesis, dietary cholesterol absorption, and removal of the
excess cholesterol from peripheral tissues. A large body of
clinical and experimental evidence suggests the hypothesis
that these finely tuned mechanisms become altered during cell
division and membrane synthesis both in physiological hyper-
proliferative conditions and in carcinogenesis (Clendening
et al., 2010; Dang, 2012). Epidemiological studies have shown
that patients with cancer have high plasma levels of lipoprotein
carriers of cholesterol and that cancer cells exhibit deregulated
transcriptional levels of several genes implicated in cholesterol
regulation and metabolism, such as low-density lipoprotein
receptor (Ldlr), hydroxyl-methyl glutaryl-coenzyme A reductase
(Hmgcr), and sterol regulatory element-binding proteins (Srebps)
(Llaverias et al., 2011; Scheinman et al., 2013).
Cholesterol Synthesis
Cholesterol is synthesized via the mevalonate pathway, an
enzymatic cascade in which the rate-limiting reduction of hy-
droxyl-methyl glutaryl-coenzyme A (HMG-CoA) to mevalonate
is catalyzed by HMGCR. The expression of all of the enzymes
acting in the cholesterol biosynthetic pathway is regulated by
SREBP transcription factor family (Sato, 2010).
In sterol-rich conditions, SREBP resides in the endoplasmic
reticulum as a high-molecular-weight precursor in a repressor
complex represented by the SREBP-cleavage activation protein
(SCAP), which acts as the cholesterol sensor changing con-
formation in a cholesterol-dependent fashion, and the anchor
insulin-induced gene (INSIG). Moreover, the cholesterol is ester-
ified by acyl-CoA cholesterol acyl transferase (ACAT) and stored
in the cytosol in the form of lipid droplets (Figure 1). In sterol-poor
conditions, SCAP escorts SREBP into the Golgi complex, where
it is cleaved by a series of proteolytic steps (Goldstein et al.,2006). The released mature transcription factor migrates into
the nucleus, where it recognizes its DNA binding sequence
and activates gene target transcription (Figure 1). Studies per-
formed on different types of tumors have revealed that cancer
cells present deficient feedback control of HMGCR or increased
HMGCR expression compared to untransformed cells, suggest-
ing that the dysregulation of the mevalonate pathway may have
the oncogenic power to drive malignant transformation (Clend-
ening et al., 2010) and sustain tumor growth (Sorrentino et al.,
2014). Moreover, mevalonate is a precursor of several major
products regulating the cell cycle, including dolichol, geranyl-
pyro-phosphate (GPP), and farnesyl-pyrophospate (FPP) (Gold-
stein and Brown, 1990). Dolichol has a stimulatory effect on DNA
synthesis and is linked to several tumor cell proteins (Wejde
et al., 1998). GPP and FPP cause isoprenylation of the intracel-
lular G proteins Ras and Rho, which in turn regulate the signal
transduction of several membrane receptors crucial for the tran-
scription of genes involved in cell proliferation, differentiation,
and apoptosis (Goldstein and Brown, 1990).
Cholesterol Influx
To sustain the whole-body cholesterol homeostatic state and
reduce the high ATP consumption of cholesterol de novo biosyn-
thesis, lipoproteins mediate the processing and delivery of die-
tary cholesterol to peripheral tissues via circulation. Low-density
lipoprotein (LDL) particles deliver cholesterol to most peripheral
tissues through a receptor-mediated mechanism (Brown and
Goldstein, 1986). LDLRs are present on the plasma membrane
of most cells and mediate the selective capture of LDL macro-
molecules, which are completely and rapidly degraded in the
lysosome. The LDL-derived cholesterol acts in the cell at several
levels, including suppression of transcription of the Hmgcr
gene through the SREBP pathway and activation of ACAT to
storage esterified cholesterol (Goldstein and Brown, 2009;
Brown and Goldstein, 1986). By inhibiting the SREBP pathway,
LDL also suppresses transcription of the Ldlr gene (Brown and
Goldstein, 1999). Lipid profiles of cancer patients display
reduction of plasma lipoprotein levels and their restoral to normal
values upon successful remission, suggesting the importance ofCell Metabolism 21, April 7, 2015 ª2015 Elsevier Inc. 517
Figure 1. Transcriptional Regulation of Cholesterol Metabolism during High and Low Intracellular Sterol Levels
In low-sterol-level conditions, in order to satisfy the enhanced requirement of cholesterol, the complex SCAP-SREBP migrates in the Golgi apparatus to be
cleaved and release the mature transcription factor SREBP, which activates cholesterol de novo synthesis via HMGCR and exogenous cholesterol capture via
LDLR or NPC1L1, specifically in enterocytes. Conversely, in high-sterol-level states, LXRs activate the transcriptional expression of transporters such as ABCA1,
ABCG5/G8, and ABCG1, which mediate cholesterol efflux from the cell. Moreover, sterol in excess is converted in esters and stocked within lipid droplets.
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feature needs to be more investigated with the aim of consid-
ering lipoprotein levels a biomarker in cancer (Solomon and
Freeman, 2011).
In addition, the intestinal epithelium is equipped with take-up
dietary and biliary cholesterol mechanisms from the gut lumen
into the enterocytes. Niemann Pick C1-like 1 (NPC1L1) is a pro-
tein localized at the brush border membrane of the enterocytes
that mediates free cholesterol absorption into the enterocytes.
In humans and nonhuman primates, it is also significantly ex-
pressed in the liver, where it transports newly secreted biliary
cholesterol back into hepatocytes, preventing excessive loss
of endogenous cholesterol. Ezetimibe, a drug that inhibits
cholesterol absorption by blocking NPC1L1 gut transporters,
was administered in a prostate cancer in vivo model showing
antitumor effects (Solomon and Freeman, 2011).
Cholesterol Efflux
Cholesterol elimination from the cells is a key process necessary
to prevent cholesterol retention and atherosclerotic lesion for-
mation. ATP-binding cassette (ABC) transporters are key medi-
ators of reverse cholesterol transport (RCT), a process by which
excess cholesterol from peripheral tissues is returned to the liver
by high-density lipoprotein (HDL) for ultimate excretion in bile.
The early steps of cholesterol efflux are controlled by ABCA1,
which is ubiquitously expressed and promotes net cholesterol
efflux to lipid-poor apoA-I leading to discoid HDL formation518 Cell Metabolism 21, April 7, 2015 ª2015 Elsevier Inc.(Vedhachalam et al., 2007). Moreover, ABCG1 cooperates with
ABCA1 in macrophages by further adding cellular lipids to the
nascent particle, which results in the maturation of HDL (Phillips,
2014). Additionally, the ABCG5/G8 transporters, localized on
the basal membrane of hepatocytes and enterocytes, inhibit
the absorption of cholesterol and plant sterols from the diet by
mediating the efflux of these sterols from enterocytes back into
the gut lumen and by promoting efficient secretion of cholesterol
and plant sterols from hepatocytes into the bile (Wang et al.,
2015).
Intracellular Cholesterol-Driven Regulation of Cell Cycle
and Apoptosis
The cell membrane contains micro-domains known as lipid rafts,
which are characterized by high cholesterol content and a
strict compartmentalization from the rest of the membrane.
These specific regions are associated with several proteins
that regulate pro-oncogenic and apoptotic pathways and are
involved in the initial stages of cancer development, tumor
growth and the potential progression to a migratory and meta-
static phenotype (Yang et al., 2014). Among key regulator pro-
teins anchored to cholesterol rafts, death receptors are notably
important because, once activated, they trigger apoptotic signal
transduction. Avoiding apoptosis is one of the main strategies
adopted by cancer cells to improve their rapid proliferative
behavior, and they achieve this by modulating the cholesterol
composition of lipid rafts, thus disrupting death receptor folding
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and the TNF-related apoptosis-inducing ligand (TRAIL), have
been extensively investigated, given their central role in
apoptosis activation. Cholesterol depletion studies show a
significant inhibition of the cell death program associated with
Fas and TRAIL (Li et al., 2006; Song et al., 2007).
Several studies have focused on oncogenic signals trans-
mitted by the Rac protein kinase (AKT) protein, a serine-threo-
nine protein kinase that mediates cell survival and growth. Since
AKT is closely associated with cholesterol rafts, many studies
indicate that changes in membrane cholesterol content deter-
mine alterations in the proliferation rate of tumor cells through
AKT signal modulation (Li et al., 2006). It was recently shown
that in prostate tumor cells, reduction of membrane cholesterol
levels causes the rearrangement of lipid rafts with strong
effects on AKT. The cholesterol-driven disruption of lipid rafts
is characterized by downregulation of the AKT signal and thus
the renovation of the apoptotic impulse (Pommier et al., 2010).
Furthermore, the cell cycle seems to be sensitive to intracellular
cholesterol. Inhibition of cholesterol synthesis mediated by
statin treatment results in breast cancer cell line arrest in the
G1 phase of the cell cycle, given the SREBP pathway activation
and then the increase of cyclin-dependent kinase inhibitors p21
and p27 (Rao et al., 1998). Moreover, the antitumoral effects
of cholesterol biosynthesis inhibition in breast carcinoma cells
have been associated with the suppression of the mitogen-acti-
vated protein kinase (MEK/Erk) pathway and the dramatic
decreases in nuclear factor kappa-B (NF-kB) and activator pro-
tein-1 (AP-1) DNA binding activities (Campbell et al., 2006).
Nuclear Receptors LXR as Transcriptional Cholesterol
Sensors
LXRs are members of the nuclear receptor (NR) superfamily of
ligand-activated transcription factors and exist as two isoforms,
LXRa and LXRb. They act as whole-body cholesterol sensors,
and their activation results in a net elimination of cholesterol
from the body and amelioration of the plasma lipoprotein profile
by mobilizing cholesterol from the periphery (Venkateswaran
et al., 2000; Repa et al., 2000b), promoting its hepatic excretion
and limiting its absorption (Repa et al., 2002; Yu et al., 2014;
Duval et al., 2006), reducing its cellular uptake (Zelcer et al.,
2009), and enhancing its conversion to bile acids in mice (Peet
et al., 1998). The identification of 24S, 25, and 27 hydroxycholes-
terol as in vivo ligands of LXR endorsed these receptors as sterol
sensors.
Identification, Cloning, and Expression Pattern
Originally considered orphan receptors, LXRs were identified
between 1994 and 1996 as RXR heterodimers permissive to
activation by both LXR and RXR ligands. LXRa and LXRb bind
to the LXR responsive element (LXRE), a specific DNA sequence
represented by two 50-AGGTCA-30 hexameric half-sites sepa-
rated by a four-nucleotide spacer (DR4 motif) (Willy et al.,
1995; Apfel et al., 1994). Following ligand binding to LXR or
RXR, corepressors are released and coactivators are recruited,
resulting in gene transcription. Studies of sequence comparison
revealed a 77% sequence homology in Lxra and Lxrb genes,
while northern blot analysis showed a different tissue distri-
bution, thus identifying LXRb as the ubiquitous isoform (Apfel
et al., 1994) and LXRa as selectively expressed in metabolicallyactive tissues such as the liver, adipose tissue, adrenal glands,
intestine, and macrophages (Chen et al., 2007).
Identification of Oxysterols as In Vivo Ligands
In 1996, Janowski and colleagues relocated LXRs as a specific
class of nuclear receptor by discovering oxysterols, mono-
oxygenated derivates of cholesterol, as LXR-specific ligands
(Janowski et al., 1996). Similarly to the assay used for ligand
identification of other receptors, concentrated lipid extracts
from different tissues were screened in a high-throughput co-
transfection assay, revealing a cholesterol-derived compound
able to transactivate LXRa (Janowski et al., 1996). Structural-
activity relationship studies (SAR) disclosed that the position
of the hydroxyl group on the cholesterol backbone is deter-
minant for LXR high-affinity binding and activation at concen-
trations occurring in vivo (Janowski et al., 1999). In general,
biological oxysterols are classified in two main categories:
those oxygenated on the sterol ring on the 7 position (e.g.,
7a/b-hydroperoxycholesterol [7OOHC], 7-ketocholesterol [7KC],
and 7a/b-hydroxy-cholesterol [7HC]) with a non-enzymatic
origin, and those oxygenated on the side chain (e.g., 24S-
hydroxycholesterol [24HC], 25-hydroxycholesterol [25HC] and
27-hydroxycholesterol [27HC]), generally produced in enzymatic
reactions.
In physiological conditions, oxysterols act as regulators of
cholesterol excess via both LXR activation and SREBP direct
regulation in an LXR-independent way. In order to prevent
SREBP maturation in Golgi apparatus and, consequently, sup-
press the expression of genes involved in sterol metabolism,
oxysterols seem to bind to INSIG, retaining the SREBP-SCAP
complex in the endoplasmic reticulum (Radhakrishnan et al.,
2007; Janowski et al., 2001). Moreover, intracellular oxysterol
storage triggers HMGCR binding to INSIG, inducing the recruit-
ment of a membrane-associated ubiquitin ligase called GP78
and thus the ubiquitination and degradation of reductase by
cytosolic 26S proteasomes (DeBose-Boyd, 2008). Finally,
oxysterols and in particular 25HC are thought to activate intra-
cellular cholesterol transport to the endoplasmic reticulum and
thus intracellular storage in the form of esterified cholesterol
(Du et al., 2004).
The LXR Transcriptome
Earlier evidence of the physiological role of LXR in lipid meta-
bolism came from LXRa knock-out mice, which, after being
fed a high-cholesterol diet, accumulated large amounts of cho-
lesteryl ester in their livers (Peet et al., 1998) and showed an
altered plasma lipoprotein profile, characterized by increased
LDL and reduced HDL cholesterol levels (Janowski et al.,
1996). Cytochrome P450 7A1 (CYP7A1), an enzyme that cata-
lyzes the rate-limiting step in bile acid synthesis and promotes
the excretion of fecal sterols (Peet et al., 1998), was identified
as the first LXR target gene in the mouse. Subsequent studies
of LXR activation in vivo revealed the unique role of LXR in pro-
moting RCT by induction of ABCA1 (Venkateswaran et al.,
2000; Repa et al., 2000b) and ABCG1 expression (Kennedy
et al., 2005). In addition, LXRs modulate intestinal cholesterol
excretion via the induction of ABCG5 and ABCG8 transporters
(Repa et al., 2002) and regulate a cluster of lipoprotein genes
as well as lipid-remodeling genes (Laffitte et al., 2003; Zhang
et al., 2001), thus increasing fecal sterol excretion. Furthermore,
the contribution of LXRs to the lowering of whole-bodyCell Metabolism 21, April 7, 2015 ª2015 Elsevier Inc. 519
Figure 2. Oxysterol and Cholesterol Homeostasis: A Finely Tuned
Clockwork Disrupted during and by Proliferative Stimuli
(A) Oxysterol hypothesis of cholesterol homeostasis. Upon intracellular low-
sterol levels, cholesterol synthesis (HMGCR) and uptake (NPC1L1 and LDLR)
are increased while cholesterol efflux via ABC transporters (A1, G1, and G5/
G8) is inhibited. Moreover, oxysterol catabolism (via SULT2B1b) and secretion
(ABCC1) are upregulated while oxysterol synthesis is repressed. On the other
hand, in the presence of intracellular high sterol levels, both cholesterol and
oxysterol metabolism are conversely regulated.
(B) Intracellular high cholesterol levels with low oxysterol levels and down-
regulated LXR/RXR transcriptional activity. Normal and cancer cells exposed
to proliferative stimuli display the uncoupling of cholesterol and oxysterol
homeostasis, via repression of LXR transcriptional activity, to increase intra-
cellular cholesterol content.
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from cholesterol de novo biosynthesis to fatty acid synthesis.
The lipogenic power of LXRs is mediated by direct upregulation
of SREBP-1c, the main regulator of hepatic lipogenesis (Repa
et al., 2000a), as well as direct induction of other lipogenic genes
such as fatty acid synthase (Fas) (Joseph et al., 2002) and
stearoyl-CoA desaturase 1 (Scd1) (Chu et al., 2006). Recent
evidence also points to the ability of LXRs to reduce intestinal
absorption of cholesterol, by the induction of the E3 ubiquitin
ligase inducible degrader of LDLR (IDOL) and subsequent
degradation of LDLR, which limits LDL cholesterol uptake in pe-
ripheral tissues (Zelcer et al., 2009). Moreover, LXR activation
downregulates NPC1L1 expression in mice and human entero-
cytes, with a consequent reduction of cholesterol absorption
(Duval et al., 2006).
In this scenario the intestine seems to be a key player in the
control of cholesterol homeostasis. Recent studies of intesti-
nal-specific LXR activation in vivo have provided evidence
that upregulation of ABCG5/ABCG8 and ABCA1 transporters
strongly reduces cholesterol absorption, increases pre-b HDL
particles, and reverses cholesterol transport in vivo in the
absence of hepatic steatosis (Lo Sasso et al., 2010b).
Uncoupling Cholesterol Homeostasis and LXR in Normal
and Cancer Cell Proliferation
Forty years ago, Kandutsch and colleagues first elaborated the
‘‘oxysterol hypothesis of cholesterol homeostasis’’ based on
the observation that oxysterols mediate feedback regulation of
cholesterol biosynthesis rather than cholesterol (Kandutsch
et al., 1978). Oxysterols are now recognized to potentially
act at multiple LXR-driven points in cholesterol homeostasis,
first by increasing cholesterol efflux gene expression, then by
decreasing cholesterol synthesis and uptake at the transcrip-
tional level via disruption of the SREBP pathway, and finally
accelerating the degradation of HMGCR. In conditions of normal
cell proliferation (Figure 2A) as well as in cancer cells (Figure 2B),
the accumulation of intracellular cholesterol is required to sus-
tain the high growth rate, and it is paradoxically coupled with a
substantial reduction of oxysterol contents, thus downregulating
the LXR transcriptome. This scenario is characterized by oxy-
sterol synthetic pathway shutdown and a boost of catabolic
and secretory cascades.
Oxysterol Metabolism: Synthesis, Catabolism, and
Secretion
Oxysterols produced via enzymatic oxidation have been exten-
sively studied, given their credibility as physiological regulators
in vivo. 24HC, 27HC, and 25HC are the main LXR biological
activators, synthesized by cytochrome P450 and non-heme
iron-containing enzymes with different tissue distribution.
Cholesterol 24-hydroxylase (CYP46A1) is a microsomal enzyme
highly expressed in neurons, where it produces the so called
‘‘cerebrosterol’’ 24HC (Bjo¨rkhem et al., 1998). Sterol 27-hydrox-
ylase (CYP27A1) converts cholesterol in 27HC and is localized
in the mitochondria of many tissues, especially the liver and
macrophages. It also catalyzes the first step in the alternative
pathway of bile acid synthesis (Russell, 2000). Cholesterol
25-hydroxylase is a small hydrophobic protein which belongs
to the non-heme iron-containing protein family and is expressed
at very low levels in most tissues. The product of its enzymatic
Table 1. In Vitro and In Vivo Evidence of Ability of LXR Activation to Inhibit Tumorigenesis
Tumor In Vitro In Vivo Reference
Breast cancer MCF7, T47D, ER-SK-BR3,
MDA-MB231
MCF7 cell-derived breast xenograft,
MMTV-PyMT mice
Gong et al., 2007; Nelson et al., 2013;
Nguyen-Vu et al., 2013; Vedin et al., 2009
Colon cancer HT29, LS174T, HCT116,
Colo205
VP16LXRa/Apcmin; LXRaKO, LXRbKO,
LXRa/bKO, HT29 cell-derived xenograft,
AOM/DSS colitis-associated carcinogenesis
Lo Sasso et al., 2013; Vedin et al.,
2009, 2013
Prostate cancer LNCaP 104-S, LNCaP 104-R2,
PC-3, DU-145
LNCaP 104-S cell-derived xenograft Chuu et al., 2006, 2007; Fu et al., 2014;
Fukuchi et al., 2004; Trasino et al., 2009
Glioblastoma U87, U87-EGFRvIII, U87-EGFR,
U87-EGFR-PTEN, LN299, T98
Human malignant glioma cells and human
primary GBM39 cell-derived xenograft
Guo et al., 2011
Melanoma B16F10, A-375, L10BIOBR B16F10 cell-derived xenograft Zhang et al., 2014; Pencheva et al., 2014
Ovarian carcinoma CaOV3, HS-68, SKOV3, A278 – Rough et al., 2010
Gallbladder cancer LXRa/, LXRb/, LXRa/b/
female mice
Gabbi et al., 2010
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cholesterol de novo biosynthesis by inhibiting SREBP matura-
tion and inducing the ubiquitination and degradation of HMGCR
in a sterol-dependent manner (Goldstein et al., 2006).
The levels of ligand for nuclear receptors are regulated by cata-
bolic enzymes. The expression of these enzymes protects from
the action of circulating ligands, and often, with a feed-forward
regulatory loop, it is the same ligand that controls its own catabo-
lism. In low-sterol conditions, oxysterols are metabolized for
inactivation and elimination from the body in order to abate the
expression of LXR transcriptome and hold cholesterol back in
the cell. One apparently widespread mechanism for the meta-
bolism of oxysterols is sulfation of the 3b-hydroxyl group by
SULT2B1b, a member of cholesterol sulfotransferase highly
expressed in human liver andmacrophages (Meloche andFalany,
2001). Chen and colleagues provided the first evidence about the
ability of sulfation to inactivate oxysterols. When SULT2B1b was
overexpressed in several cell lines and in cholesterol-fed mice,
the attenuationof cholesterol capacity to induceLXR target genes
such as Cyp7a1, Srebp1-c, Abcg5, and Abcg8 was observed
(Chenetal., 2007).Besides inactivatingoxysterols asLXR ligands,
sulfation increases their polarity and thus facilitates their efflux
from the cell by membrane transporters such as multidrug re-
sistance-associated protein 1 (ABCC1). ABCC1 is a membrane-
bound protein involved in the cellular defense mechanism,
generally localized in the basolateral membrane of polarized cells
(Evers et al., 1996) and expressed almost ubiquitously inmany tis-
sues (Flenset al., 1996). LikemanyotherABCCmembers, ABCC1
pumps anticancer drugs, xenobiotics, andmetabolites like inacti-
vated oxysterols into the extracellular space in order to prevent
toxicity such as carcinogenesis (Kunicka´ and Soucek, 2014; Le-
slie et al., 2005). However, these transportersmay also contribute
to themultidrug resistance, which occurs in cancer treatment fail-
ure, rendering tumor cells protected by many drugs and chemo-
therapeutics (Kunicka´ and Soucek, 2014).
Antitumoral Effects of LXR Activation: Putative
Mechanisms of Action
Many recent studies on pharmacological LXR activation in colon,
breast, prostate, gallbladder, and skin cancer cells (Table 1)
report the antiproliferative effect of LXR mediated by the alter-ation of tumor metabolism (Lo Sasso et al., 2013; Nelson et al.,
2013) and microenvironment (El Roz et al., 2013; Pencheva
et al., 2014; Wang et al., 2014), disruption of key growth path-
ways (Vedin et al., 2009, 2013; Uno et al., 2009), and activation
of apoptotic processes (Zhang et al., 2014; Wente et al., 2007;
Pommier et al., 2010).
Since LXR and tumor metabolism relationship is in-depth
described in the next paragraph, the other putative LXR-medi-
ated mechanisms of tumor growth inhibition are mentioned
below. As observed in breast (Vedin et al., 2009), colon (Lo Sasso
et al., 2013; Vedin et al., 2013), and prostate (Fukuchi et al., 2004)
cancer studies, activated LXR leads to cell-cycle arrest via
downregulation of SKP2 (S phase-associated kinase protein-2),
a component of ubiquitin ligase that regulates the degradation
of p27kip1, one of the inhibitors of cell-cycle progression from
G1 to S phase (Fukuchi et al., 2004). Studies performed on
both estrogen receptor (ER)-positive and -negative breast can-
cer cell lines support the strong relationship between LXR and
estrogen-signaling pathway, highlighting a more pronounced
antiproliferative effect of LXR activation in ER-positive cells
than ER-negative ones (Vedin et al., 2009). Further experiments
performed by Nguyen-Vu and colleagues suggest the involve-
ment of E2F2, a member of the E2F family of transcription
factors. In ER-positive breast cancer cell lines, E2F2 seems to
be downregulated after treatment with LXR agonists, thereby
blocking proliferation (Nguyen-Vu et al., 2013). In prostate cancer
cells, cholesterol depletion induced by LXR alters lipid raft
composition, thus disrupting the correct folding and the activa-
tion state of proteins (i.e., AKT) that regulate downstream path-
ways crucial in cell survivors (Pommier et al., 2010). Candelaria
and colleagues have studied LXR activation effects in pancreatic
ductal adenocarcinoma cell lines (Candelaria et al., 2014) and
have observed the downregulation of growth factor signaling,
especially epidermal growth factor receptor (EGFR) activation,
as previously described by Guo in glioblastoma cells (Guo
et al., 2011). Furthermore, a new interesting mechanism of
LXR modulating tumor microenvironment has been observed
by Pencheva and colleagues in melanoma cancer models.
They have observed LXR’s ability in suppressing tumor invasion
and angiogenesis by transcriptionally activating melanoma
cell secretion of apolipoprotein E (APOE), a potent metastasisCell Metabolism 21, April 7, 2015 ª2015 Elsevier Inc. 521
Figure 3. LXR Transcriptome in Normal and Cancer Cell
In normal cells, LXR transcriptional activity ensures an adequate intracellular sterol content via activation (ABCA1, ABCG1, ABCG5/ABCG8) or repression
(NPC1L1 and LDLR) of its direct target genes. Of note, LXR activation is sustained by the prevalence of oxysterol anabolism (CYP4A1, CYP2A1, and Chol-25-
hydroxylase) over catabolism (ABCC1 and SULT2B1b). In cancer cells, despite the intracellular cholesterol abundance, LXR transcriptome is downregulated as a
result of the metabolic shift of oxysterol metabolism from anabolic toward catabolic pathways.
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released within the tumor microenvironment, acts by suppress-
ing melanoma invasion ability by targeting LDLR-related protein
1 (LRP-1 receptor) on melanoma cells and endothelial recruit-
ment and migration via LDLR-related protein 8 (LRP8) receptors
(Pencheva et al., 2012). The tumor microenvironment is full of
cytokines that play an important role in intercellular communi-
cation and in the inflammatory processes occurring in the
tumor. Interferon-g (IFN-g) is one of the cytokines involved in anti-
proliferative, antiangiogenic, and proapoptotic effects against
cancer cells (Zaidi and Merlino, 2011). IFN-g especially targets
macrophages, thus activating tumor cell cytotoxicity, antimicro-
bial activity, intracellular pathogen removal, and acquired im-
mune responses (MacMicking et al., 1997). In a recent study,
Wang and colleagues identified IFN-g as a new putative molecu-
lar target of LXR activation. In in vivo experiments, administration
of LXR ligand inoculated with lung tumor cells increases IFN-g
production, rates of survival, and tumor-free animals, an effect
not observed in IFN-g/ mice, suggesting that the inhibition of
tumor growth happens in an IFN-g-dependent manner (Wang
et al., 2014). Moreover, Blanc and colleagues have found that
IFN is directly coupled with 25HC via an LXR-independent
but SREBP-dependent subordinate mechanism, highlighting a
previously unrecognized biological role for 25HC (Blanc et al.,
2013). They have also observed that IFN-treated macrophages
secrete more 25HC, suggesting a potential regulatory role of
25HC and LXR in IFN-based cancer treatment.
The Normal and Cancer Cholesterol-LXR Uncoupling
Models
In vivo experiments provide evidence that tumor-unrelated
cell proliferation, such as proliferating T cells (Bensinger et al.,522 Cell Metabolism 21, April 7, 2015 ª2015 Elsevier Inc.2008) and liver regeneration after partial hepatectomy (Lo Sasso
et al., 2010a), as well as tumor-related hyperproliferation status,
are closely associated with enhanced cholesterol requirement,
which is satisfied not only by upregulating de novo biosynthesis
but also by increasing cholesterol uptake via LDLR. In most of
these studies, it has been observed that LXR synthetic ligands
are able to decrease cell growth and to induce significant
tumor cell death in vivo, thanks to their ability to repress LDLR
protein expression via IDOL activation, inhibit HMGCR activity,
and induce cholesterol efflux via ABCA1, ABCG5, and ABCG8
(Figure 3) (Moschetta, 2011). Below are detailed hyperprolifera-
tive and cancer models of uncoupling cholesterol homeostasis
with LXR activity.
Acquired Immune Response in T Cells
Adaptive immune responses are carried out by lymphocytes
that, upon pathogen-associated immunostimulation, undergo
rapid and extensive proliferation in order to defend the organism
against infection. This characteristic of T cell function is sus-
tained by lipid metabolism modulation and sterol intracellular
availability, an unknown regulatory role that Bensinger and col-
leagues have elegantly revealed in a recent study (Bensinger
et al., 2008). During T cell activation and proliferation, the transi-
tion from G1 to the S phase is realized by metabolic reprogram-
ming, in which LXR-mediated downregulation of transporters
ABCA1 and ABCG1 increases sterol concentration. Further-
more, LXR null mice show splenomegaly and lymphadenopathy
typical of T and B cell expansion. Conversely, the ligand acti-
vation of LXR inhibits proliferative stimuli by decreasing sterol
contents through ABCG1 upregulation. These data confirm the
existence of an endogenous sterol signaling pathway regulating
lymphocyte proliferation through LXR. The unexpected mecha-
nism by which LXR transcriptome is downregulated during
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by way of SULT2B1 overexpression (Chen et al., 2007; Fuda
et al., 2007). The definition of a SULT2B1-LXR-ABCG1 axis
that couples cellular cholesterol metabolism and proliferation
has represented a milestone in understanding the basis of lipid
role and regulation, with main relevance to rapid dividing cells.
Liver Regeneration after Partial Hepatectomy
The regenerating mouse liver is an effective model in vivo to
study the modulation of cholesterol metabolism during cell
proliferation. Since 1985, Field and collaborators have employed
regenerating rat liver post-partial hepatectomy to investigate
the effect of cell proliferation on plasma and liver metabolism,
showing that during hepatic regeneration, triglyceride and
cholesterol levels significantly decrease in plasma but increase
in the liver (Field et al., 1985). Given LXR’s ability to act as the
sensor of cholesterol homeostasis, Lo Sasso and colleagues
have investigated the mechanism by which LXR controls choles-
terol hepatic contents in regeneratingmouse liver (LoSassoet al.,
2010a). Theyconfirmed increased intrahepatic cholesterol levels,
explained by the induction of cholesterol de novo biosynthesis
and inhibition of catabolism into bile acids and biliary secretion.
This event is characterized by the downregulation of the entire
LXR transcriptome, including transporters ABCG5 and ABCG8,
and the loss of its inhibitory effect on cholesterol intracellular
accumulation. Moreover, significant changes in the expression
of genes encoding for proteins and enzymes involved in oxysterol
synthesis (CYP27A1 and CYP46A1), catabolism (SULT2B1b),
and secretion (ABCC1) were measured in cholesterol-enriched
proliferating hepatocytes. These data suggest that oxysterol
deprivation determines the switch-off of LXR transcriptional ac-
tivity. Accordingly, mice lacking LXRa and LXRb (LXRa/b/)
show no differences in their hepatic regenerative ability because
the absence of LXRsmimics the ligand inactivation status of LXR
transcriptome normally observed during liver regeneration.
In this scenario the loss of the feedback regulatory loop be-
tween cholesterol and oxysterol homeostasis drives hepatocyte
regenerative capacity in order to feed cells with the cholesterol
amount required to sustain liver regeneration (Lo Sasso et al.,
2010a).
Cancer Models
The role of LXR in carcinogenesis (Chuu and Lin, 2010; Fukuchi
et al., 2004) has been recently investigated in different tumor
types such as glioblastoma, colon cancer, breast cancer, and
prostate cancer.
Glioblastoma is the most common and lethal malignant brain
tumor in adults. It is characterized by rapidly proliferating cancer
cells with highly activated oncogenic pathways and signal trans-
duction effectors that alter themetabolic status in order to satisfy
the enhanced tumor cell requirement for cholesterol (Choe et al.,
2003). A recent study by Guo and colleagues provided a new
point of view on the molecular mechanisms by which cancer
cells obtain cholesterol. The authors proved the existence of
a phosphatidylinositide 3-kinase/SREBP-1 (PI3K/SREBP-1)-
dependent tumor survival pathway, driven by a mutated and
constitutively activated form of EGFR, which increases LDLR
expression and provides cancer cells with the cholesterol
required, bypassing cholesterol de novo biosynthesis. In this
intriguing metabolic scenario, LXR is a key player in inducing,
upon ligand activation, LDLR degradation via IDOL expressionand determining glioblastoma cell growth arrest and cell death
(Guo et al., 2011).
Tumor protective action of LXR has also been observed in a
recent colon cancer study. Given the well-known role of choles-
terol as a metabolic driver of cellular proliferation and the
LXR role in regulating enterocyte cholesterol homeostasis,
Lo Sasso and colleagues employed many in vitro and in vivo
models of LXR activation in tumorigenesis. A xenograft study
of colon cancer cells as well as Apcmin mice and familial
adenomatous polyposis patients, which spontaneously develop
intestinal tumors, showed protection against cancer cell growth
upon LXR activation. Furthermore, microarray analysis points to
LXR-driven cholesterol depletion at the basis of the antitumoral
scenario (Lo Sasso et al., 2013).
Breast cancer is the most common feminine cancer and,
despite the improvement in early diagnosis and treatment, is the
secondhighest causeof cancer death. Evidence indicating hyper-
cholesterolemia and metabolic syndrome as particularly impor-
tant risk factors for breast cancer led investigators to study
cholesterol involvement in breast tumorigenesis. The interesting
discovery of these studies allocates oxysterols, particularly
27HC, as a selective ERmodulator able to promote tumor growth.
Moreover, the observation that elevated levels of CYP7B1, a cyto-
chrome p450 monooxygenase responsible for the catabolism of
27HC, are associated with a better survival outcome supports
the involvement of a regulatory role of oxysterol in breast tumori-
genesis (Nelson et al., 2013). Conversely, Gong and colleagues
endorse LXRs as metabolic deactivators of estrogen, given their
ability to induce cholesterol conversion in bile acids and establish
estrogen depletion status (Gong et al., 2007). However, this sce-
nario is murine-specific since LXR does not activate CYP7A1 in
the human liver. Similarly, cholesterol involvement in promoting
prostate cancer development has been well established in recent
years. The observation that LXRsignaling is attenuated in prostate
cancerprogression fromanandrogen-dependent toanandrogen-
independent status and that the growth arrest occurredwhenLXR
is re-activated by synthetic ligands endorse LXR signaling as a
new target for controlling cancer cell proliferation (Chuu et al.,
2006, 2007; Fukuchi et al., 2004).
The LXR Bona Fide Therapeutic Strategy in Cancer
Cellular cholesterol levels depend on integrated activities of
synthesis, uptake, and efflux that are impaired in conditions of
high-rate cell proliferation, especially tumor-related ones. There-
fore, targeting cholesterol homeostasis could represent a valid
therapeutic approach in cancer treatment, and several strategies
that impact cell and blood cholesterol levels have been studied.
A first approach in many in vitro and in vivo studies has been
represented by the use of HMGCR inhibitors to block the
mevalonate pathway and cholesterol de novo biosynthesis
(Clendening et al., 2010; Clendening and Penn, 2012; Ginestier
et al., 2012). Despite the promising results, statins seem to
be ineffective as an antitumor drug because cancer cells gain
selective proliferative power by enhancing LDLR-mediated
uptake of exogenous cholesterol (Guo et al., 2011).
Studies on LXR activation in multiple tumor types (Table 1)
have shown significant cell growth arrest and apoptotic pathway
activation, endorsing the antitumoral power of LXR by modu-
lating metabolism, microenvironment, and cell cycle.Cell Metabolism 21, April 7, 2015 ª2015 Elsevier Inc. 523
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PerspectiveLXR activation promotes cholesterol removal from cells by
increasing the expression of membrane transporters ABCA1,
ABCG5, ABCG8, and ABCG1 and inhibits exogenous uptake
via LDLR by inducing IDOL-mediated LDLR degradation. More-
over, targeting LXRs may be a powerful and novel approach
given their ability to regulate both cholesterol and fatty acid
metabolism. Most studies in cancer biology have been focused
on increased expression and activity of FAS, responsible for the
de novo fatty acid synthesis. In physiological conditions, FAS
activity is regulated by insulin and nutritional status via the
induction of SREBP, which increases the expression of genes
involved in lipid metabolism. In cancer cells, FAS seems to be
sensitive to signal transduction pathways associated with a
malignant phenotype (Van de Sande et al., 2005), and the
hypothesis of its potential role as an oncogene (Baron et al.,
2004) is supported by the need of cancer cells to supply the
required energy by fatty acid oxidation (Liu, 2006). On the con-
trary, FAS inhibition is associated with the suppression of cell
proliferation, adhesion, migration, and invasion, thus attenuating
the malignant tumor phenotype (Yoshii et al., 2013). Although
in cancer cells fatty acid synthesis is upregulated, and LXR acti-
vation could enhance the lipid feeding, in this review we provide
evidence of LXR’s ability to block cell proliferation, and we
suggest the combined administration of LXR agonists and fatty
acid synthase inhibitors as a potential therapeutic combination
in cancer therapy. Moreover, LXR ligands could be a powerful
approach in treating many tumors, given their action on both
cell cycle and microenvironment. LXR activation has been
reported to suppress cancer cell proliferation by disrupting key
growth pathways, such as ER and EGFR, or downregulating
tumor-promoting molecules such as SKP2, blocking cell-cycle
progression from G1 to S phase (Candelaria et al., 2014; Vedin
et al., 2009). Additionally, LXRs are able to modulate tumor
microenvironment composition by enhancing the production of
antimetastatic and antiangiogenic molecules such as APOE
(Pencheva et al., 2014) and by activating the immune system
via the action of IFN (Blanc et al., 2013;Wang et al., 2014). Future
translational studies are urgently needed to identify eventual
LXR-dependent side effects and to launch LXR agonism as a
novel antitumor co-adjuvant strategy.ACKNOWLEDGMENTS
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